Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results

International Journal of Urology

Volumn 11, Issue 5, 2004, Pages 295-303

  Homma, Yukio ^a,j   Akaza, Hideyuki ^b   Okada, Kiyoki ^c   Yokoyama, Masao ^d   Moriyama, Nobuo ^a   Usami, Michiyuki ^e   Hirao, Yoshihiko ^f   Tsushima, Tomoyasu ^g   Sakamoto, Atsuhiko ^h   Ohashi, Yasuo ^a   Aso, Yoshio ⁱ  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c NIHON UNIVERSITY   (Japan)

^d TORANOMON HOSPITAL   (Japan)

^e OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^f NARA MEDICAL UNIVERSITY   (Japan)

^g OKAYAMA UNIVERSITY   (Japan)

^h KYORIN UNIVERSITY   (Japan)

ⁱ FUJIEDA MUNICIPAL GENERAL HOSPITAL   (Japan)

^j JAPANESE RED CROSS MEDICAL CENTER   (Japan)

more..

Author keywords

Endocrine therapy; Preoperative androgen deprivation; Prostate cancer; Radical prostatectomy

Indexed keywords

ANDROGEN; CHLORMADINONE ACETATE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; MALE; METASTASIS; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; CHLORMADINONE ACETATE; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREOPERATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 2942564152     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2004.00795.x     Document Type: Article

References (26)

1. Boyle P, Napalkov P, Barry MJ et al. Epidemiology and natural history of prostate cancer. In: Murphy G, Griffiths K, Denis L, Khoury S, Chatelain C, Cockett AT (eds). The First International Consultation on Prostate Cancer. Scientific Communication International, Paris, 1996; 1-30.
2. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-54.
3. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J. Urol. 1994; 152: 1831-6.
4. Rosen MA, Goldstone L, Lapin S, Wheeler T, Scardino PT. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J. Urol. 1992; 148: 331-7.
5. Debruyne FM, Dijkman GA. Advances and trends in hormonal therapy for advanced prostate cancer. Eur. Urol. 1995; 28: 177-88.
6. Van Poppel H, De Ridder D, Elgamal AA et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. J. Urol. 1995; 154: 429-34.
7. Hellstrom M, Haggman M, Pedersen K, Busch C, Brandstedt S. A 3-year follow-up of patients with localized prostate cancer operated on with or without pretreatment with the GnRH-agonist triptorelin. Br. J. Urol. 1996; 78: 432-6.
8. Soloway MS, Pareek K, Sharifi R et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results. J. Urol. 2002; 167: 112-6.
9. Aus G, Abrahamsson PA, Ahlgren G et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int. 2002; 90: 561-6.
10. Selli C, Montrironi R, Bono A et al. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J. Clin. Pathol. 2002; 55: 508-13.
11. Gomella LG, Liberman SN, Mulholland SG, Petersen RO, Hyslop T, Corn BW. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial. Urology 1996; 47: 870-7.
12. Fair WR, Betancourt JE. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer. Mol. Urol. 2000; 4: 241-8.
13. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur. Urol. 2000; 38: 706-13.
14. Powell IJ, Tangen CM, Miller GJ et al. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year follow-up, Phase II Southwest Oncology Group Study 9109. J. Urol. 2002; 168: 2016-9.
15. Homma Y, Akaza H, Okada K et al. Preoperative endocrine therapy for clinical stage A2, B, and C prostate cancer: an interim report on short-term effects. Prostate Cancer Study Group. Int. J. Urol. 1997; 4: 144-51.
16. Homma Y, Akaza H, Okada K et al. Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group. Int. J. Urol. 1999; 6: 229-37; discussion 238-9.
17. Japanese Urological Association, The Japanese Society of Pathology (eds). General rule for clinical and pathological studies on prostatic cancer, 2nd edn. Kanahara Publishing Co., Tokyo, 1992 (in Japanese).
18. Smith DM, Murphy WM. Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation. Cancer 1994; 73: 1472-7.
19. Kuriyama M, Akimoto S, Akaza H et al. Comparison of various assay systems for prostate-specific antigen standardization. Jpn. J. Clin. Oncol. 1992; 22: 393-9.
20. Cheng WS, Frydenberg M, Bergstralh EJ, Larson-Keller JJ, Zincke H. Radical prostatectomy for pathologic stage C prostate cancer: influence of pathologic variables and adjuvant treatment on disease outcome. Urology 1993; 42: 283-91.
21. Freeman JA, Lieskovsky G, Cook DW et al. Radical retropubic prostatectomy and postoperative adjuvant radiation for pathological stage C (PcN0) prostate cancer from 1976 to 1989: intermediate findings. J. Urol. 1976; 149: 1029-34.
22. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J. Urol. 1995; 154: 1818-24.
23. Watson RB, Civantos F, Soloway MS. Positive surgical margins with radical prostatectomy: detailed pathological analysis and prognosis. Urology 1996; 48: 80-90.
24. Gerber GS, Thisted RA, Chodak GW et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur. Urol. 1997; 32: 385-90.
25. van den Ouden D, Davidson PJ, Hop W, Schroder FH. Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer. J. Urol. 1994; 151: 646-51.
26. Samson DJ, Seidenfeld J, Schmitt B et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95: 361-76.